What Rheumatoid Arthritis Is Actually Doing to Your Body

Start Here

Series: The Rheumatoid Arthritis Articles | Part 1 of 3

Most people with rheumatoid arthritis are managing a joint disease. That's what they've been told they have. Their rheumatologist tracks the joint inflammation. The medications are aimed at joint inflammation. The appointments monitor what the joints are doing. The conversation stays at the joint level.

Rheumatoid arthritis is not a joint disease.

The joints are where it's most visible. They're not where it originates, and they're not where it does its most serious damage. The majority of patients with rheumatoid arthritis are never told this. Understanding it is the difference between managing a condition for the rest of your life and understanding what would actually need to change for it to improve.

The Risk Most Rheumatoid Arthritis Patients Don't Know They're Carrying

People with chronic inflammatory conditions including rheumatoid arthritis carry a 45 to 60 percent higher risk of sudden cardiac death compared to the general population. That number deserves to sit for a moment before moving past it.

Sudden cardiac death means no warning. No escalating symptoms over weeks that give a window to respond. The first sign of that particular cardiac event is the event itself. For a significant percentage of people with rheumatoid arthritis, the cardiovascular system is being compromised in parallel with the joints, quietly, measurably, and largely outside the scope of what the standard rheumatology appointment is tracking.

Rheumatoid arthritis also reduces life expectancy. Research places the reduction at a decade or more in many patients. Dr. Betty Diamond, director of the Institute of Molecular Medicine at Northwell Health, has stated directly that almost all autoimmune diseases decrease life expectancy. The mechanism behind that reduction is the same one driving the joints. Managing the joints doesn't stop the mechanism.

Rheumatoid arthritis carries a 45 to 60 percent higher risk of sudden cardiac death. Sudden means the first symptom is the event itself. The joints are not the only system being damaged.

None of this is being shared to create fear. It's being shared because the standard framing of rheumatoid arthritis as a joint condition systematically underrepresents how much is at stake. Patients who understand the full picture of what their condition is doing are in a far better position to ask the questions that actually matter.

What Google's Own AI Says About the Cause

When you search "mitochondrial DNA damage and rheumatoid arthritis" on Google, the AI Overview that appears uses a specific word to describe the relationship. That word is pathogenesis.

Pathogenesis means the origin of the disease process. It means starting point. In medical terminology, pathogenesis is not a description of a contributing factor or a downstream effect. It's the description of the mechanism by which the disease develops. When Google's AI uses that word to describe the relationship between mitochondrial DNA damage and rheumatoid arthritis, it's describing causation, not correlation.

The full statement from that AI Overview: mitochondrial DNA damage and dysfunction are significant factors in rheumatoid arthritis pathogenesis, contributing to chronic inflammation and joint destruction. This reflects what the published research has been showing for years. The mechanism driving rheumatoid arthritis originates in the mitochondria. The joints are where the damage becomes visible. The mitochondria are where it starts.

Google's AI Overview describes mitochondrial DNA damage as a pathogenic driver of rheumatoid arthritis, meaning the mechanism that produces the disease. The joints are where RA becomes visible. The mitochondria are where it originates.

What Is Actually Happening in the Joints and Beyond

Research shows that up to 70 percent of rheumatoid arthritis patients have elevated extracellular mitochondrial DNA in their synovial fluid, the fluid inside the joint. In healthy people without rheumatoid arthritis, this is largely absent. The presence of that damaged mitochondrial DNA in the joint space is not a coincidence. It's the mechanism.

When mitochondria sustain damage, they release mitochondrial DNA into the surrounding tissue and into the circulation. The immune system reads that released DNA as a damage signal, a pattern it recognizes as indicating that something has gone wrong at the cellular level. That signal triggers an inflammatory response through pathways including TLR9, which drives the production of pro-inflammatory cytokines. Those cytokines produce the joint inflammation. That joint inflammation produces the pain, swelling, and stiffness that most patients experience as the condition itself.

The inflammation didn't start because the immune system malfunctioned. It started because the mitochondria sent a distress signal. The immune system responded to that signal correctly. The problem is the signal keeps coming, because the source of the damage keeps running.

The specific antibody pattern in someone's blood reflects exactly where in the mitochondria the damage is concentrated. When the damage is at Complex One of the electron transport chain, the person tests positive for rheumatoid factor. When the damage is at the mitochondrial DNA itself, the person tests positive for anti-citrullinated protein antibodies, the anti-CCP marker. Both patterns originate in the same mitochondrial energy system. The location of the damage determines which antibody shows up in the lab results. This is why two people with the same diagnosis can have completely different lab patterns.

The inflammatory cascade in rheumatoid arthritis originates in damaged mitochondria releasing distress signals. The immune system responds correctly to those signals. The problem is the signal doesn't stop, because the source of the damage continues.

How the Damage Spreads Beyond the Joints

The same mitochondrial damage driving the joint destruction isn't confined to joint tissue. Mitochondria are present in every cell in the body. When the energy system that governs mitochondrial function is compromised systemically, the damage accumulates in multiple tissue types simultaneously.

The cardiovascular system is particularly vulnerable because the heart has the highest concentration of mitochondria of any organ. It cannot rest, it cannot skip a cycle, it requires uninterrupted energy production every second of every day. When the mitochondrial energy system is compromised, the cardiovascular system feels that compromise in a way that compounds over time. The 45 to 60 percent elevated cardiac death risk in rheumatoid arthritis patients is not a separate disease process running alongside the arthritis. It's the same process expressing itself in cardiac tissue.

Research has also identified circulating mitochondrial DNA levels in the blood as a prognostic marker for RA-associated interstitial lung disease, with higher mitochondrial DNA levels correlating with increased mortality. The lungs. The cardiovascular system. The joints. The same marker, the same origin, the same process playing out in different tissues.

Bone erosion in rheumatoid arthritis follows the same logic. Osteoclasts, the cells responsible for bone breakdown, become overactive when mitochondrial dysfunction disrupts the normal balance between bone resorption and rebuilding. The cartilage and bone destruction that patients see in imaging is the downstream result of mitochondrial damage driving cellular behavior that the joint tissue can't regulate correctly.

The mitochondrial damage driving rheumatoid arthritis affects every tissue where mitochondria exist. The cardiac risk, the lung involvement, and the bone erosion are not separate problems. They're the same cellular energy failure expressed in different locations.

The Direct Line Between Damage Level and Disease Severity

One of the most clinically significant findings in rheumatoid arthritis research is that there is a direct correlation between the degree of mitochondrial DNA damage and the severity of the disease. More damage produces worse disease. Less damage corresponds to less severe presentation.

This correlation matters for a specific reason. It means that the disease is not random. It's not an unpredictable malfunction of the immune system that waxes and wanes based on factors that can't be measured or influenced. The severity tracks directly with a measurable biological variable. Which means that variable, the degree of mitochondrial DNA damage, is the target that determines outcomes.

Tumor necrosis factor alpha, one of the primary cytokines involved in rheumatoid arthritis, follows the same pattern. Research published in 2007 showed a direct correlation between TNF-alpha levels and mortality. Higher TNF-alpha means faster disease progression. TNF-alpha is also what many of the biologic medications for rheumatoid arthritis are designed to block. Blocking it reduces the inflammatory signal downstream. It doesn't address the mitochondrial damage generating the signal upstream. The damage continues accumulating. The signal keeps being generated. The medication keeps blocking it.

This isn't a criticism of the practitioners prescribing those medications. They're working within a system designed to manage the outputs of the condition. It's an explanation of why the condition continues to progress in patients who are successfully managed on those medications. Management of the output and resolution of the source are different outcomes requiring different approaches.

What This Means for How Rheumatoid Arthritis Is Being Treated

Understanding that rheumatoid arthritis originates in mitochondrial damage changes the question that needs to be asked about treatment. The current standard of care is designed around a different question: how do we reduce the inflammatory output? That question produces useful answers for managing symptoms. It doesn't produce answers for reversing the source.

Part 2 of this series,

Why RA Medications Don't Stop the Damage, covers exactly how the standard medication approach works, what it's targeting, and why patients who are successfully managed on those medications still see their condition advance over time. If you've been told your labs look good but you still don't feel well, that article explains the mechanism behind that experience.

Part 3,

What Actually Has to Change for RA to Improve, covers the specific clinical framework for addressing the mitochondrial damage at the source, what that evaluation looks like, and what the intervention sequence requires.

If you want the foundational explanation of why mitochondrial energy production is the common driver across chronic illness broadly, the article

The Real Reason Your Body Isn't Healing (Energetic Debt Explained) is the place to start.

Find Out What the Mitochondrial Damage Pattern Looks Like in Your Case

The specific damage location determines which antibody pattern shows up in your labs.

It also determines what the intervention needs to target.

[ BOOK YOUR CONSULTATION ]

Dr. Rob DeMartino D.C. | Energetic Debt Method

This article is educational and does not constitute individual medical advice. Outcomes vary by patient and condition.

Frequently Asked Questions

These questions reflect what patients commonly search when they're trying to understand why rheumatoid arthritis is affecting more than their joints and whether the current treatment approach is addressing the actual cause.

Is rheumatoid arthritis a joint disease or a systemic disease?

Rheumatoid arthritis is a systemic disease that expresses most visibly in the joints. The mechanism driving it, mitochondrial DNA damage triggering inflammatory distress signals, operates throughout the body wherever mitochondria exist. That includes the cardiovascular system, the lungs, and bone tissue. Research shows that patients with RA carry a 45 to 60 percent higher risk of sudden cardiac death compared to the general population, and circulating mitochondrial DNA levels are used as a prognostic marker for RA-associated lung disease. Treating only the joint inflammation addresses the most visible output of the condition without touching the mechanism producing it.

What causes rheumatoid arthritis at the cellular level?

The published research, including Google's AI search summary, describes mitochondrial DNA damage as a pathogenic driver of rheumatoid arthritis. Pathogenesis means the origin of the disease process, not a contributing factor. When mitochondria sustain damage, they release mitochondrial DNA into surrounding tissue. The immune system reads this as a damage signal and generates an inflammatory response through pathways including TLR9. That inflammation produces the cytokines that drive joint destruction. The immune system is responding correctly to the signal it's receiving. The problem is the signal keeps coming because the source of the damage continues.

Why do some RA patients test positive for rheumatoid factor and others for anti-CCP antibodies?

Both antibody patterns originate in mitochondrial damage, but the specific location of the damage determines which marker appears. When the damage is concentrated at Complex One of the electron transport chain, the person typically tests positive for rheumatoid factor. When the damage is at the mitochondrial DNA itself, anti-citrullinated protein antibodies, the anti-CCP marker, appear instead. This is why two people with the same diagnosis can have completely different lab patterns. The damage location determines both the antibody pattern and, by extension, which cytokines are being generated and which medications will have the most effect on the inflammatory output.

Can rheumatoid arthritis affect the heart?

Yes, and the mechanism is direct rather than incidental. The heart has the highest concentration of mitochondria of any organ, because it requires continuous uninterrupted energy production. The same mitochondrial energy failure driving the joint damage in RA affects cardiac tissue through the same pathway. Research documents a 45 to 60 percent elevated risk of sudden cardiac death in people with chronic inflammatory conditions including RA. Sudden cardiac death means no prior warning symptoms, which is why this risk doesn't get caught through standard monitoring. Managing joint inflammation through medication does not reduce the mitochondrial damage accumulating in cardiac tissue.

Is the severity of rheumatoid arthritis predictable or random?

Research shows a direct correlation between the degree of mitochondrial DNA damage and disease severity in rheumatoid arthritis. More damage produces worse disease presentation. This means the severity is not random. It tracks with a measurable biological variable, which also means it's a variable that can potentially be addressed. The standard treatment model doesn't measure or target mitochondrial DNA damage. It measures inflammatory markers, which are the output of that damage, and uses medications to reduce those outputs. The damage itself continues accumulating regardless of how well the inflammatory markers are managed.

Why does rheumatoid arthritis reduce life expectancy?

The life expectancy reduction in RA, which research places at a decade or more in many patients, comes from the systemic nature of the underlying mechanism. The mitochondrial damage driving the condition affects every tissue where mitochondria are present. The cardiovascular involvement alone accounts for a significant portion of the elevated mortality. Additionally, the research on mitochondrial leakiness shows a direct correlation between how much mitochondria are leaking and how fast biological aging accelerates. A person with unaddressed mitochondrial damage is aging faster at the cellular level than their chronological age would suggest, independent of how well their joint inflammation is being managed.

Does methotrexate or biologics stop rheumatoid arthritis from getting worse?

Methotrexate, biologics, and JAK inhibitors reduce the inflammatory signals that produce joint damage. They do this by targeting cytokines like TNF-alpha or blocking specific immune pathways. What they don't do is address the mitochondrial DNA damage generating those signals in the first place. Research published in 2007 showed that TNF-alpha levels correlate directly with mortality in rheumatoid arthritis. Medications that block TNF-alpha reduce the measurable level of that marker without stopping the mitochondrial damage that causes the body to produce it. Part 2 of this series covers this mechanism in detail.

Can rheumatoid arthritis actually be reversed or is management the only option?

The conventional medical position is that rheumatoid arthritis is not curable and that management is the goal. This position is based on the assumption that the mechanism driving it cannot be addressed directly, which is accurate within a treatment model that only has pharmaceutical tools targeting cytokine outputs. If the mechanism is mitochondrial DNA damage producing inflammatory distress signals, and that damage can be assessed and addressed at the energy system level, the premise changes. Part 3 of this series covers what addressing the mechanism rather than its outputs actually involves and what that evaluation looks like.

Conventional medical care vs. Superior Health Solutions natural healthcare

Related video